Comment on "Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis"

Johanne Pereira Ribeiro¹, Mie Sedoc Jørgensen^{2

3

4}, Ole Jakob Storebø^{2

3

5}

Affiliations

¹ Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark. joper@regionsjaelland.dk.
² Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark.
³ Department of Child and Adolescent Psychiatry, Psychiatry Region Zealand, Roskilde, Denmark.
⁴ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁵ Department of Psychology, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Comment

Johanne Pereira Ribeiro et al. CNS Drugs. 2021 Dec.

. 2021 Dec;35(12):1333-1334.

doi: 10.1007/s40263-021-00872-3. Epub 2021 Nov 7.

Johanne Pereira Ribeiro¹, Mie Sedoc Jørgensen^{2

3

4}, Ole Jakob Storebø^{2

3

5}

¹ Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark. joper@regionsjaelland.dk.
² Psychiatric Research Unit, Psychiatry Region Zealand, Slagelse, Denmark.
³ Department of Child and Adolescent Psychiatry, Psychiatry Region Zealand, Roskilde, Denmark.
⁴ Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁵ Department of Psychology, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

No abstract available

Comment in

Authors' Reply to Pereira Ribeiro et al.: Comment on "Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta‑Analysis".
Gartlehner G, Crotty K, Edlund MJ, Viswanathan M. Gartlehner G, et al. CNS Drugs. 2021 Dec;35(12):1335-1336. doi: 10.1007/s40263-021-00873-2. Epub 2021 Nov 7. CNS Drugs. 2021. PMID: 34743294 No abstract available.

Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis.
Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, Fortman R, Wines R, Persad E, Viswanathan M. Gartlehner G, et al. CNS Drugs. 2021 Oct;35(10):1053-1067. doi: 10.1007/s40263-021-00855-4. Epub 2021 Sep 8. CNS Drugs. 2021. PMID: 34495494 Free PMC article.

1. Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, et al. Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis. CNS Drugs. 2021;35(10):1053–67. https://doi.org/10.1007/s40263-021-00855-4 . - DOI - PubMed - PMC
1. Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66(7):726–35. - DOI
1. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol. 2013;66(7):736–42. - DOI
1. Sterne J, Savović J, Page M, Elbers R, Blencowe N, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. - DOI
1. de la Fuente J, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4(4):479–86. - DOI